Lonza and Chr. Hansen Join to Accelerate Momentum in Microbiome

Denmark-based Chr. Hansen Holding A/S and Lonza AG have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture will be a 50/50 controlled legal entity that will ...